Back to Journals » Psoriasis: Targets and Therapy » Volume 12
Psoriasis: Targets and Therapy
ISSN: 2230-326X
- View all (142)
- Volume 14, 2024 (9)
- Volume 13, 2023 (7)
- Volume 12, 2022 (22)
- Volume 11, 2021 (14)
- Volume 10, 2020 (8)
- Volume 9, 2019 (13)
- Volume 8, 2018 (12)
- Volume 7, 2017 (9)
- Volume 6, 2016 (15)
- Volume 5, 2015 (13)
- Volume 4, 2014 (5)
- Volume 3, 2013 (4)
- Volume 2, 2012 (10)
- Volume 1, 2011 (1)
Archive: Volume 12, 2022
Assessment of Vitamin D Level in Patients with Psoriasis and Its Correlation with Disease Severity: A Case–Control Study
Pokharel R, Agrawal S, Pandey P, Lamsal M
Psoriasis: Targets and Therapy 2022, 12:251-258
Published Date: 13 September 2022
Towards Personalized Medicine in Psoriasis: Current Progress
Camela E, Potestio L, Ruggiero A, Ocampo-Garza SS, Fabbrocini G, Megna M
Psoriasis: Targets and Therapy 2022, 12:231-250
Published Date: 1 September 2022
Therapeutic Inertia in the Management of Psoriasis: A Quantitative Survey Among Indian Dermatologists and Patients
Rajagopalan M, Dogra S, Godse K, Kar BR, Kotla SK, Neema S, Saraswat A, Shah SD, Madnani N, Sardesai V, Sekhri R, Varma S, Arora S, Kawatra P
Psoriasis: Targets and Therapy 2022, 12:221-230
Published Date: 25 August 2022
Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis
Gisondi P, Bellinato F, Maurelli M, Geat D, Zabotti A, McGonagle D, Girolomoni G
Psoriasis: Targets and Therapy 2022, 12:213-220
Published Date: 10 August 2022
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
Megna M, Potestio L, Fabbrocini G, Ruggiero A
Psoriasis: Targets and Therapy 2022, 12:205-212
Published Date: 14 July 2022
Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study
Megna M, Fornaro L, Potestio L, Luciano MA, Nocerino M, Delfino M, Guarino M, Fabbrocini G, Camela E
Psoriasis: Targets and Therapy 2022, 12:199-204
Published Date: 9 July 2022
Psoriasis and Exercise: A Review
Yeroushalmi S, Hakimi M, Chung M, Bartholomew E, Bhutani T, Liao W
Psoriasis: Targets and Therapy 2022, 12:189-197
Published Date: 2 July 2022
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management [Corrigendum]
Al-Janabi A, Yiu ZZN
Psoriasis: Targets and Therapy 2022, 12:187-188
Published Date: 1 July 2022
Dimethyl Fumarate as Therapeutic Alternative in Moderate-to-Severe Psoriasis: Our Experience
Rosés Gibert P, de la Torre Gomar FJ, Saenz Aguirre A, Gimeno Castillo J, González Pérez R
Psoriasis: Targets and Therapy 2022, 12:177-185
Published Date: 29 June 2022
Dietary Intervention and Supplements in the Management of Psoriasis: Current Perspectives
Chung M, Bartholomew E, Yeroushalmi S, Hakimi M, Bhutani T, Liao W
Psoriasis: Targets and Therapy 2022, 12:151-176
Published Date: 22 June 2022
Comorbidity in Adult Psoriasis: Considerations for the Clinician
Daugaard C, Iversen L, Hjuler KF
Psoriasis: Targets and Therapy 2022, 12:139-150
Published Date: 10 June 2022
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M
Psoriasis: Targets and Therapy 2022, 12:127-137
Published Date: 8 June 2022
Comorbid Psoriasis and Metabolic Syndrome: Clinical Implications and Optimal Management
De Brandt E, Hillary T
Psoriasis: Targets and Therapy 2022, 12:113-126
Published Date: 25 May 2022
Biologics Can Significantly Improve Dermatology Life Quality Index (DLQI) in Psoriatic Patients: A Systematic Review
de Ruiter CC, Rustemeyer T
Psoriasis: Targets and Therapy 2022, 12:99-112
Published Date: 24 May 2022
Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study
Löfvendahl S, Norlin JM, Schmitt-Egenolf M
Psoriasis: Targets and Therapy 2022, 12:89-98
Published Date: 5 May 2022
Updated Perspectives on Keratinocytes and Psoriasis: Keratinocytes are More Than Innocent Bystanders
Ortiz-Lopez LI, Choudhary V, Bollag WB
Psoriasis: Targets and Therapy 2022, 12:73-87
Published Date: 2 May 2022
The Efficacy and Tolerability of Turmeric and Salicylic Acid in Psoriasis Treatment
Draelos ZD
Psoriasis: Targets and Therapy 2022, 12:63-71
Published Date: 29 April 2022
An Open-Label, Randomized, Prospective, Comparative, Three-Arm Clinical Trial to Evaluate the Safety and Effectiveness of Apremilast with Three Different Titration Methods in Patients with Chronic Plaque Psoriasis in India
Viswanath V, Joshi P, Lawate P, Tare D, Dhoot D, Mahadkar N, Barkate H
Psoriasis: Targets and Therapy 2022, 12:53-61
Published Date: 22 April 2022
The Effect of Lifestyle Changes on Disease Severity and Quality of Life in Patients with Plaque Psoriasis: A Narrative Review
van Acht MR, van den Reek JMPA, de Jong EMGJ, Seyger MMB
Psoriasis: Targets and Therapy 2022, 12:35-51
Published Date: 9 April 2022
Assessing and Improving Psychological Well-Being in Psoriasis: Considerations for the Clinician
Blackstone B, Patel R, Bewley A
Psoriasis: Targets and Therapy 2022, 12:25-33
Published Date: 25 March 2022
Telemedicine and e-Health in the Management of Psoriasis: Improving Patient Outcomes – A Narrative Review
Havelin A, Hampton P
Psoriasis: Targets and Therapy 2022, 12:15-24
Published Date: 16 March 2022
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
Al-Janabi A, Yiu ZZN
Psoriasis: Targets and Therapy 2022, 12:1-14
Published Date: 6 January 2022